article thumbnail

CBN: The Sleep-Inducing Cannabinoid

Kind Meds (Cannabis Education Blog)

CBN is a popular cannabinoid, but what should we know about CBN and sleep? This minor cannabinoid has always existed in the cannabis plant in small quantities, but it is gaining in popularity for its potential healing properties. Unlike some other cannabinoids, it is not present in substantial amounts in fresh cannabis flower.

Sleep 94
article thumbnail

Getting to Know Cannabigerol with Bonni Goldstein, MD

Project CBD

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. Dr. Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Serious Conditions Are Responding To Cannabinoid Therapy

Peninsula Alternative Health

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. However, because cannabinoids reduce seizures through numerous mechanisms of actions, possible drug interactions are still unclear. References Staff, T.

article thumbnail

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Veriheal

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

article thumbnail

Fragile X Syndrome Market Spotlight Report 2021: 10-year Disease Incidence and Prevalence Forecasts, Probability of Success, Licensing and Asset Acquisition Deals, Drug-specific Revenue Forecasts – ResearchAndMarkets.com

Cannabis Law Report

Based on cohorts of children with special educational needs, the prevalence of fragile X syndrome (FXS) is estimated to be 1 in 4,000 in males, and 1 in 8,000 in females. The majority of industry-sponsored drugs in active clinical development for FXS are in Phase II, with two drugs in Phase III. CLINICAL TRIAL LANDSCAPE.

article thumbnail

Serious Conditions Are Responding To Cannabinoid Therapy

Peninsula Alternative Health

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. However, because cannabinoids reduce seizures through numerous mechanisms of actions, possible drug interactions are still unclear. References Staff, T.

article thumbnail

These Patient Advocacy Groups Are Working Together to Expand the Scope of Cannabis Research

Veriheal

In turn, cannabis advocates have struggled to properly educate the public with the limited amount of scientific evidence available. Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy.